open access

Vol 23, No 2 (2016)
INTERVENTION/VALVULAR HEART DISEASE - Original articles
Published online: 2016-04-29
Get Citation

Paravalvular leak after transcatheter aortic valve implantation (TAVI): Short-term results. Data from Polish national POL-TAVI registry

Paweł Kleczyński, Wojciech Zasada, Maciej Bagieński, Łukasz Rzeszutko, Danuta Sorysz, Robert Sobczyński, Jarosław Trębacz, Bogdan Kapelak, Marian Zembala, Dariusz Dudek
DOI: 10.5603/CJ.a2015.0071
·
Pubmed: 26503080
·
Cardiol J 2016;23(2):163-168.

open access

Vol 23, No 2 (2016)
INTERVENTION/VALVULAR HEART DISEASE - Original articles
Published online: 2016-04-29

Abstract

Background: The authors analyzed data from Polish national POL-TAVI registry in terms of paravalvular leak (PVL) occurrence after transcatheter aortic valve implantation (TAVI) and its impact on clinical outcomes.

Methods: A total of 331 patients with severe aortic stenosis underwent TAVI (Edwards Sapien, n = 141; CoreValve, n = 190). The grade of PVL and survival rate were assessed at 6-month follow-up.

Results: One hundred and eighty-one (54.7%) patients developed mild PVL, and 22 (6.6%) — moderate PVL after TAVI. No severe PVLs were observed. Occurrence of moderate PVL was device dependent and more frequent in the CoreValve group (p = 0.02). Larger CoreValve device used correlated with the grade of PVL (Spearman: r = 0.19; p = 0.01), but for Edwards Sapien devices this correlation was inverted (Spearman: r = –0.62; p = 0.01). Six-month mortality rate was not significant between patients with no or mild PVL compared to those with moderate PVL (p = 0.12).

Conclusions: The PVL occurrence remains a frequent problem after TAVI and is device de­pendent, more common with Edwards 23 mm valve and 31 mm CoreValve prosthesis

Abstract

Background: The authors analyzed data from Polish national POL-TAVI registry in terms of paravalvular leak (PVL) occurrence after transcatheter aortic valve implantation (TAVI) and its impact on clinical outcomes.

Methods: A total of 331 patients with severe aortic stenosis underwent TAVI (Edwards Sapien, n = 141; CoreValve, n = 190). The grade of PVL and survival rate were assessed at 6-month follow-up.

Results: One hundred and eighty-one (54.7%) patients developed mild PVL, and 22 (6.6%) — moderate PVL after TAVI. No severe PVLs were observed. Occurrence of moderate PVL was device dependent and more frequent in the CoreValve group (p = 0.02). Larger CoreValve device used correlated with the grade of PVL (Spearman: r = 0.19; p = 0.01), but for Edwards Sapien devices this correlation was inverted (Spearman: r = –0.62; p = 0.01). Six-month mortality rate was not significant between patients with no or mild PVL compared to those with moderate PVL (p = 0.12).

Conclusions: The PVL occurrence remains a frequent problem after TAVI and is device de­pendent, more common with Edwards 23 mm valve and 31 mm CoreValve prosthesis

Get Citation

Keywords

aortic stenosis, high-risk patients, TAVI, paravalvular leak

About this article
Title

Paravalvular leak after transcatheter aortic valve implantation (TAVI): Short-term results. Data from Polish national POL-TAVI registry

Journal

Cardiology Journal

Issue

Vol 23, No 2 (2016)

Pages

163-168

Published online

2016-04-29

DOI

10.5603/CJ.a2015.0071

Pubmed

26503080

Bibliographic record

Cardiol J 2016;23(2):163-168.

Keywords

aortic stenosis
high-risk patients
TAVI
paravalvular leak

Authors

Paweł Kleczyński
Wojciech Zasada
Maciej Bagieński
Łukasz Rzeszutko
Danuta Sorysz
Robert Sobczyński
Jarosław Trębacz
Bogdan Kapelak
Marian Zembala
Dariusz Dudek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl